The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.
University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL acts as the data controller of the register data.
and the funding research partners:
AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.
In cooperation with the Finnish Biobank cooperative FINBB and these Finnish biobanks:
- Auria Biobank
- Helsinki Biobank
- Hematological Biobank (FHRB Biobank)
- Biobank of Eastern Finland
- Central Finland Biobank
- Northern Finland Biobank Borealis
- Finnish Clinical Biobank Tampere
- THL Biobank
- Blood Service Biobank